Authors: Barry, C Cole, S Fourie, B Geiter, L Gosey, L Grosset, J Kanyok, T Laughon, B Mitchison, D Nunn, P O'Brien, R Robinson, T Annick-Mouries, M Cynamon, M Duncan, K Goldberger, M Gutteridege, W Kioy, D Pablos-Mendez, A Orme, I Rieder, H Roscigno, G Vernon, A

Citation: C. Barry et al., Scientific blueprint for tuberculosis drug development - Global alliance for TB drug development, TUBERCULOSI, 81, 2001, pp. 1-52

Authors: Orme, I Secrist, J Anathan, S Kwong, C Maddry, J Reynolds, R Poffenberger, A Michael, M Miller, L Krahenbuh, J Adams, L Biswas, A Franzblau, S Rouse, D Winfield, D Brooks, J

Citation: I. Orme et al., Search for new drugs for treatment of tuberculosis, ANTIM AG CH, 45(7), 2001, pp. 1943-1946

Authors: Dow, SW Roberts, A Vyas, J Rodgers, J Rich, RR Orme, I Potter, TA

Citation: Sw. Dow et al., Immunization with f-Met peptides induces immune reactivity against Mycobacterium tuberculosis, TUBERC LUNG, 80(1), 2000, pp. 5-13

Authors: Kirman, J McCoy, K Hook, S Prout, M Delahunt, B Orme, I Frank, A Le Gros, G

Citation: J. Kirman et al., CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection, INFEC IMMUN, 67(8), 1999, pp. 3786-3792

Authors: Ehlers, S Kutsch, S Benini, J Cooper, A Hahn, C Gerdes, J Orme, I Martin, C Rietschel, ET

Citation: S. Ehlers et al., NOS2-derived nitric oxide regulates the size, quantity and quality of granuloma formation in Mycobacterium avium-infected mice without affecting bacterial loads, IMMUNOLOGY, 98(3), 1999, pp. 313-323